Justin C Mason

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1332901/publications.pdf

Version: 2024-02-01

94433 95266 4,836 83 37 68 h-index citations g-index papers 89 89 89 7361 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. Cardiovascular Research, 2020, 116, 2177-2184.	3.8	331
2	Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. European Heart Journal, 2015, 36, 482-489.	2.2	321
3	Takayasu arteritis—advances in diagnosis and management. Nature Reviews Rheumatology, 2010, 6, 406-415.	8.0	268
4	Activation of Nrf2 in Endothelial Cells Protects Arteries From Exhibiting a Proinflammatory State. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1851-1857.	2.4	216
5	Statins and the vascular endothelial inflammatory response. Trends in Immunology, 2007, 28, 88-98.	6.8	194
6	Exosomes secreted by cardiomyocytes subjected to ischaemia promote cardiac angiogenesis. Cardiovascular Research, 2017, 113, 1338-1350.	3.8	193
7	Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. European Heart Journal, 2009, 30, 1837-1843.	2.2	191
8	The Endothelial Transcription Factor ERG Promotes Vascular Stability and Growth through Wnt/ \hat{l}^2 -Catenin Signaling. Developmental Cell, 2015, 32, 82-96.	7.0	190
9	Bifunctional role for VEGF-induced heme oxygenase-1 in vivo: induction of angiogenesis and inhibition of leukocytic infiltration. Blood, 2004, 103, 761-766.	1.4	182
10	Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nature Reviews Rheumatology, 2017, 13, 578-592.	8.0	161
11	Detection of increased levels of circulating intercellular adhesion molecule 1 in some patients with rheumatoid arthritis but not in patients with systemic lupus erythematosus. lack of correlation with levels of circulating vascular cell adhesion molecule 1. Arthritis and Rheumatism, 1993, 36, 519-527.	6.7	148
12	Imaging of Vascular Inflammation With [11C]-PK11195 and Positron Emission Tomography/Computed Tomography Angiography. Journal of the American College of Cardiology, 2010, 56, 653-661.	2.8	138
13	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology, 2020, 59, e1-e23.	1.9	128
14	Induction of Decay-Accelerating Factor by Cytokines or the Membrane-Attack Complex Protects Vascular Endothelial Cells Against Complement Deposition. Blood, 1999, 94, 1673-1682.	1.4	107
15	Statins and their role in vascular protection. Clinical Science, 2003, 105, 251-266.	4.3	100
16	Induction of the Cytoprotective Enzyme Heme Oxygenase-1 by Statins Is Enhanced in Vascular Endothelium Exposed to Laminar Shear Stress and Impaired by Disturbed Flow. Journal of Biological Chemistry, 2009, 284, 18882-18892.	3.4	96
17	PKCε-CREB-Nrf2 signalling induces HO-1 in the vascular endothelium and enhances resistance to inflammation and apoptosis. Cardiovascular Research, 2015, 106, 509-519.	3.8	89
18	Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase $C\hat{a}\in ``dependent pathway protects vascular endothelial cells from complement-mediated injury. Blood, 2000, 96, 2784-2792.$	1.4	87

#	Article	IF	Citations
19	Statin-Induced Expression of Decay-Accelerating Factor Protects Vascular Endothelium Against Complement-Mediated Injury. Circulation Research, 2002, 91, 696-703.	4.5	85
20	Heme oxygenase-1 expression enhances vascular endothelial resistance to complement-mediated injury through induction of decay-accelerating factor: a role for increased bilirubin and ferritin. Blood, 2009, 113, 1598-1607.	1.4	83
21	Takayasu arteritis: advanced understanding is leading to new horizons. Rheumatology, 2019, 58, 206-219.	1.9	82
22	Large-vessel vasculitis. Nature Reviews Disease Primers, 2021, 7, 93.	30.5	74
23	Dynamic regulation of canonical $TGF\hat{l}^2$ signalling by endothelial transcription factor ERG protects from liver fibrogenesis. Nature Communications, 2017, 8, 895.	12.8	70
24	Detection and Quantification of Large-Vessel Inflammation with ¹¹ C-(<i>R</i>)-PK11195 PET/CT. Journal of Nuclear Medicine, 2011, 52, 33-39.	5.0	68
25	Investigational Analysis Reveals a Potential Role for Neutrophils in Giant-Cell Arteritis Disease Progression. Circulation Research, 2014, 114, 242-248.	4.5	68
26	Integrated cardiac and vascular assessment in Takayasu arteritis by cardiovascular magnetic resonance. Arthritis and Rheumatism, 2009, 60, 3501-3509.	6.7	61
27	KLF2-dependent, Shear Stress-induced Expression of CD59. Journal of Biological Chemistry, 2008, 283, 14636-14644.	3.4	60
28	Celecoxib activates PI-3K/Akt and mitochondrial redox signaling to enhance heme oxygenase-1-mediated anti-inflammatory activity in vascular endothelium. Free Radical Biology and Medicine, 2010, 48, 1013-1023.	2.9	56
29	PPARδ and PGC1α act cooperatively to induce haem oxygenase-1 and enhance vascular endothelial cell resistance to stress. Cardiovascular Research, 2010, 85, 701-710.	3.8	55
30	Multi-functional mechanisms of immune evasion by the streptococcal complement inhibitor C5a peptidase. PLoS Pathogens, 2017, 13, e1006493.	4.7	55
31	Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: A mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis. Arthritis and Rheumatism, 2001, 44, 138-150.	6.7	50
32	bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction. American Journal of Physiology - Cell Physiology, 2002, 282, C578-C587.	4.6	48
33	Decay-accelerating Factor Induction on Vascular Endothelium by Vascular Endothelial Growth Factor (VEGF) Is Mediated via a VEGF Receptor-2 (VEGF-R2)- and Protein Kinase C-α/ε (PKCα/Ĩµ)-dependent Cytoprotective Signaling Pathway and Is Inhibited by Cyclosporin A. Journal of Biological Chemistry, 2004, 279, 41611-41618.	3.4	46
34	A Protein Kinase Cε-Anti-apoptotic Kinase Signaling Complex Protects Human Vascular Endothelial Cells against Apoptosis through Induction of Bcl-2. Journal of Biological Chemistry, 2007, 282, 32288-32297.	3.4	45
35	Zebrafish Model for Functional Screening of Flow-Responsive Genes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 130-143.	2.4	45
36	Decay-Accelerating Factor Suppresses Complement C3 Activation and Retards Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice. American Journal of Pathology, 2009, 175, 1757-1767.	3.8	41

#	Article	IF	CITATIONS
37	Takayasu arteritis. Current Opinion in Rheumatology, 2015, 27, 45-52.	4.3	40
38	Decay-accelerating factor induction by tumour necrosis factor-alpha, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition. Immunology, 2003, 110, 258-268.	4.4	38
39	Surgical intervention and its role in Takayasu arteritis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 112-124.	3.3	36
40	Celecoxib exerts protective effects in the vascular endothelium via COX-2-independent activation of AMPK-CREB-Nrf2 signalling. Scientific Reports, 2018, 8, 6271.	3.3	34
41	Novel Angiographic Scores for evaluation of Large Vessel Vasculitis. Scientific Reports, 2018, 8, 15979.	3.3	34
42	Statin-induced expression of CD59 on vascular endothelium in hypoxia: a potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis. Arthritis Research and Therapy, 2006, 8, R130.	3.5	32
43	FDG Uptake by Prosthetic Arterial Grafts in Large Vessel Vasculitis Is NotÂSpecific for Active Disease. JACC: Cardiovascular Imaging, 2017, 10, 1042-1052.	5.3	31
44	A cohort study reveals myocarditis to be a rare and life-threatening presentation of large vessel vasculitis. Seminars in Arthritis and Rheumatism, 2017, 47, 241-246.	3.4	28
45	Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF- $\hat{l}\pm$ and IL-6 receptor targeted therapies in refractory Takayasu arteritis. Clinical and Experimental Rheumatology, 2014, 32, S11-8.	0.8	28
46	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. American Journal of Human Genetics, 2021, 108, 84-99.	6.2	26
47	Blood Biomarkers for Monitoring and Prognosis of Large Vessel Vasculitides. Current Rheumatology Reports, 2021, 23, 17.	4.7	23
48	The statins - therapeutic diversity in renal disease?. Current Opinion in Nephrology and Hypertension, 2005, 14, 17-24.	2.0	22
49	Application of imaging techniques for Takayasu arteritis. Presse Medicale, 2017, 46, e215-e223.	1.9	22
50	Novel Positron Emission Tomography Tracers for Imaging Vascular Inflammation. Current Cardiology Reports, 2020, 22, 119.	2.9	22
51	Cytoprotective pathways in the vascular endothelium. Do they represent a viable therapeutic target?. Vascular Pharmacology, 2016, 86, 41-52.	2.1	21
52	Novel Approach to Imaging Active Takayasu Arteritis Using Somatostatin Receptor Positron Emission Tomography/Magnetic Resonance Imaging. Circulation: Cardiovascular Imaging, 2020, 13, e010389.	2.6	18
53	Identification of cyclins A1, E1 and vimentin as downstream targets of heme oxygenase-1 in vascular endothelial growth factor-mediated angiogenesis. Scientific Reports, 2016, 6, 29417.	3.3	18
54	Giant cell arteritis: new concepts, treatments and the unmet need that remains. Rheumatology, 2019, 58, 1123-1125.	1.9	17

#	Article	IF	CITATIONS
55	The Clinical Importance of Leucocyte and Endothelial Cell Adhesion Molecules in Inflammation. Vascular Medicine Review, 1994, vmr-5, 249-275.	0.3	16
56	Proarrhythmic electrophysiological and structural remodeling in rheumatoid arthritis. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 319, H1008-H1020.	3.2	16
57	Pericoronary and periaortic adipose tissue density are associated with inflammatory disease activity in Takayasu arteritis and atherosclerosis. European Heart Journal Open, 2021, 1, oeab019.	2.3	15
58	Issues in trial design for ANCA-associated and large-vessel vasculitis. Nature Reviews Rheumatology, 2014, 10, 502-510.	8.0	7
59	Adalimumab-induced remission of anterior scleritis: a very rare late manifestation of Takayasu arteritis: Fig. 1. Rheumatology, 2015, 54, kev324.	1.9	7
60	Isolation and Analysis of Large and Small Vessel Endothelial Cells. Methods in Molecular Medicine, 2007, 135, 305-321.	0.8	7
61	Identification of an activated neutrophil phenotype in polymyalgia rheumatica during steroid treatment: a potential involvement of immune cell cross-talk. Clinical Science, 2019, 133, 839-851.	4.3	6
62	Biologic therapy in supra-aortic Takayasu arteritis can improve symptoms of cerebral ischaemia without surgical intervention. Rheumatology, 2020, 59, iii28-iii32.	1.9	6
63	Simultaneous presentation of IgG4-related chronic peri-aortitis and coeliac disease in a patient with Marfan's Syndrome. Rheumatology, 2016, 55, 1141-1143.	1.9	5
64	The Impact of Integrated NoninvasiveÂlmaging in the Management of Takayasu Arteritis. JACC: Cardiovascular Imaging, 2021, 14, 495-500.	5.3	4
65	Clinical trial protocol: PRednisolone in early diffuse cutaneous Systemic Sclerosis (PRedSS). Journal of Scleroderma and Related Disorders, 2021, 6, 146-153.	1.7	4
66	Pauciâ€immune glomerulonephritis: the <scp>ANCA</scp> â€negative side of the coin. International Journal of Rheumatic Diseases, 2016, 19, 5-7.	1.9	3
67	A rare life-threatening presentation of Takayasu arteritis. Rheumatology, 2021, 60, iii6-iii8.	1.9	3
68	The role of statins in vascular protection. Clinical Advances in Hematology and Oncology, 2007, 5, 352-4.	0.3	3
69	Investigation of the regulatory role of heme oxygenase-1 and its products in VEGF-mediated angiogenesis. Vascular Pharmacology, 2012, 56, 345.	2.1	2
70	270â€∱Real life experience of tocilizumab for Takayasu arteritis. Rheumatology, 2019, 58, .	1.9	2
71	Vessel wall magnetic resonance and arterial spin labelling imaging in the management of presumed inflammatory intracranial arterial vasculopathy. Brain Communications, 0, , .	3.3	2
72	Drugs for inflammation and joint disease. , 2012, , 240-259.		1

#	Article	IF	CITATIONS
73	Intervention in Takayasu Aortitis: When, Where and How?. Hearts, 2020, 1, 62-74.	0.9	1
74	Vascular Endothelial Cell Adhesion Molecules and the Control of Leukocyte Traffic in Cutaneous Inflammation. Advances in Molecular and Cell Biology, 1999, , 323-344.	0.1	0
75	MAP KINASE PHOSPHATASE-1 SUPPRESSES ENDOTHELIAL ACTIVATION IN REGIONS OF THE ARTERIAL TREE THAT ARE RESISTANT TO ATHEROSCLEROSIS. Atherosclerosis, 2008, 199, 465.	0.8	O
76	Cytoprotective Mechanisms in the Vasculature. , 2012, , 27-43.		0
77	145 Marked improvement in symptoms of cerebral ischaemia in response to immunosuppressive therapy in severe supra-aortic Takayasu arteritis. Rheumatology, 2018, 57, .	1.9	0
78	i119 Vascular rheumatology: endothelium, inflammation and imaging. Rheumatology, 2018, 57, .	1.9	0
79	206.â€∱PLASMA MICROVESICLE ANALYSIS IN TAKAYASU ARTERITIS REVEALS A DISTINCT ENDOTHELIAL AND PLATELET PHENOTYPE. Rheumatology, 2019, 58, .	1.9	O
80	Cutaneous Polyarteritis Nodosa Presenting Atypically with Severe Pharyngeal Ulceration. Case Reports in Rheumatology, 2019, 2019, 1-4.	0.6	0
81	P183â \in f Assessing the safety of treatment cessation in Takayasu arteritis. Rheumatology, 2020, 59, .	1.9	O
82	Image-Based Computational Hemodynamics and Microarray Analysis of the Porcine Aortic Arch Reveals a Correlation Between Shear Stress and Endothelial Cell Apoptosis. , 2012, , .		0
83	Heme Oxygenase-1 and Atherosclerosis. , 0, , 301-323.		O